Sotoxen 320 mg (Sotorasib INN)
KRAS G12C Inhibitor for Targeted Lung Cancer Therapy
💊 Pharmacology:
Sotorasib is a selective KRAS G12C inhibitor that works by:
- Irreversibly binding to the mutated KRAS G12C protein
- Locking it in an inactive state
- Inhibiting downstream signaling pathways responsible for tumor growth
- Reducing cancer cell proliferation and survival
This targeted mechanism offers precision treatment for patients with KRAS-driven tumors.
📌 Indications:
Sotoxen® 320 mg is indicated for:
- Locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Patients with confirmed KRAS G12C mutation
- Disease progression after prior systemic therapy
💉 Dosage & Administration:
- Recommended dose: 960 mg once daily (typically 3 tablets of 320 mg)
- Taken orally with or without food
- Swallow tablets whole; do not crush or chew
- Continue treatment until disease progression or unacceptable toxicity
⚠️ Must be used under oncologist supervision.
⚠️ Precautions & Warnings:
- Monitor liver function tests (ALT, AST) regularly
- Risk of hepatotoxicity
- Monitor for interstitial lung disease (ILD)/pneumonitis
- Avoid use with strong CYP3A inducers/inhibitors
- Caution in patients with pre-existing lung disease
❌ Contraindications:
- Hypersensitivity to Sotorasib or any formulation component
🤰 Pregnancy & Lactation:
- Not recommended during pregnancy
- Breastfeeding should be avoided during treatment
- Use effective contraception during therapy
⚕️ Side Effects:
Common side effects include:
- Diarrhea
- Nausea
- Fatigue
- Elevated liver enzymes
- Musculoskeletal pain
Serious but less common:
- Hepatotoxicity
- Interstitial lung disease/pneumonitis
🧊 Storage Conditions:
- Store below 30°C
- Keep in a cool, dry place
- Protect from light and moisture
- Keep out of reach of children
